Ian W. Flinn, MD, PhD

Ian W. Flinn, MD, PhD, is the director of Lymphoma Research at the Sarah Cannon Research Institute. In this role, he oversees lymphoma research throughout Sarah Cannon and its affiliates. He also serves as the director of the Sarah Cannon Center for Blood Cancers at Tennessee Oncology. 

Dr Flinn’s research focuses on the development of new therapies for patients with lymphoma and chronic lymphocytic leukemia. This research includes first-in-human to phase 3 trials with novel approaches such as immune effector cell therapies, inhibitors of the B-cell receptor pathway, and BCL-2 inhibitors, among others. His research has been widely published in journals such as The New England Journal of Medicine, The Lancet, the Journal of Clinical Oncology, and Blood.